(19)
(11) EP 4 504 763 A1

(12)

(43) Date of publication:
12.02.2025 Bulletin 2025/07

(21) Application number: 23720701.4

(22) Date of filing: 06.04.2023
(51) International Patent Classification (IPC): 
C07K 14/54(2006.01)
A61P 35/00(2006.01)
 A61K 38/20(2006.01)
(52) Cooperative Patent Classification (CPC):
C07K 14/5434; A61K 38/20; C07K 2319/50
(86) International application number:
PCT/US2023/065429
(87) International publication number:
WO 2023/196897 (12.10.2023 Gazette 2023/41)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
KH MA MD TN

(30) Priority: 07.04.2022 US 202263328708 P
07.11.2022 US 202263382694 P

(71) Applicant: WEREWOLF THERAPEUTICS, INC.
Watertown, MA 02472 (US)

(72) Inventors:
  • WINSTON, William
    Watertown, MA 02472 (US)
  • SEIDEL-DUGAN, Cynthia
    Watertown, MA 02472 (US)
  • HICKLIN, Daniel
    Watertown, MA 02472 (US)
  • BRODKIN, Heather
    Watertown, MA 02472 (US)
  • SALMERON-GARCIA, Jose, Andres
    Watertown, MA 02472 (US)
  • STEINER, Philipp
    Watertown, MA 02472 (US)
  • NIRSCHL, Christopher
    Watertown, MA 02472 (US)

(74) Representative: Mathys & Squire 
The Shard 32 London Bridge Street
London SE1 9SG
London SE1 9SG (GB)

   


(54) IL-12 PRODRUGS